EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Blastic Plasmacytoid Dendritic Cell Neoplasm ( BPDCN ): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management

Shai Shimony iD, Marlise R Luskin iD, Naseema Gangat iD, Nicole R LeBoeuf, Angela M Feraco, Andrew A Lane

American Journal of Hematology · 2025-08 · 100 (8) · 1408-1422

DOI: 10.1002/ajh.27737 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 17.06.2025. Verfasst von Shai Shimony und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Hematologic Neoplasms, Skin Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 82 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overview Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic neoplasm that involves multiple organs, including the skin, bone marrow and blood, lymph nodes, and central nervous system. Violaceous tumors or plaques appearing in sun‐exposed areas are characteristic and present in most patients. The disease typically affects adult men aged 60–70 years, although children and younger adults may also be affected. Diagnosis Diagnosis is based on biopsy of an involved site and is typically based on the identification of blastoid cells displaying the classical immunophenotypes CD123, CD4, and CD56 in addition to specific pDC markers. Prognosis The median overall survival is 18–24 months. Potential risk factors for shortened survival include older age, overt bone marrow involvement, and genetic abnormalities. Therapy and Management Either chemotherapy‐based regimens or tagraxofusp, a CD123‐directed interleukin 3 conjugated with diphtheria toxin, may be used for upfront therapy. Eligible patients are recommended to be consolidated with hematopoietic allogeneic stem cell transplantation. Assessment and treatment of the central nervous system is mandatory, and careful monitoring of skin disease in conjunction with dermatology is essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsHematologic NeoplasmsSkin NeoplasmsHumansMiddle AgedRisk AssessmentMaleAgedDisease ManagementPrognosisRisk FactorsHematopoietic Stem Cell TransplantationBlastic Plasmacytoid Dendritic Cell NeoplasmRecombinant Fusion Proteins

Stichwörter der Autor:innen

BPDCNdiagnostic criteriatagraxofusp

Substanzen

tagraxofuspRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts, USA.
  • Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Shai Shimony, Marlise R Luskin, Naseema Gangat

Zitieren

APA

Shimony, S., Luskin, M. R., Gangat, N., LeBoeuf, N. R., Feraco, A. M., & Lane, A. A. (2025). Blastic Plasmacytoid Dendritic Cell Neoplasm ( BPDCN ): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management. American Journal of Hematology, 100(8), 1408-1422. https://doi.org/10.1002/ajh.27737

Vancouver

Shimony S, Luskin MR, Gangat N, LeBoeuf NR, Feraco AM, Lane AA. Blastic Plasmacytoid Dendritic Cell Neoplasm ( BPDCN ): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management. American Journal of Hematology. 2025;100(8):1408-1422. doi:10.1002/ajh.27737

BibTeX
@article{Shimony2025,
  author = {Shimony, Shai and Luskin, Marlise R and Gangat, Naseema and LeBoeuf, Nicole R and Feraco, Angela M and Lane, Andrew A},
  title = {Blastic Plasmacytoid Dendritic Cell Neoplasm ( BPDCN ): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {8},
  pages = {1408--1422},
  doi = {10.1002/ajh.27737}
}
Kostenlos starten →